Patient Resources

At Titan, we are committed to developing breakthrough medicines to meet the needs of patients struggling with life-altering diseases. We understand that access to information regarding diseases and clinical trials is essential to patients and their caregivers, so please view our Clinical Trials page for information regarding our ongoing clinical trials.

Schizophrenia

More than 2 million Americans suffer from schizophrenia, a severe mental illness characterized by a myriad of symptoms ranging from hallucinations, delusions, paranoia and disorganized speech and/or thinking. Titan is developing iloperidone, an atypical antipsychotic in development for the potential treatment of schizophrenia. Vanda submitted an NDA for iloperidone to the FDA in 2007 – a PDUFA date has been set for July 2008. For more information regarding iloperidone clinical trials, please click here or visit www.clinicaltrials.gov.

For more information about schizophrenia, please visit the following organizations:

Opioid Addiction

There are currently more than 6 million opioid addicts worldwide, suffering from addictions to illegal substances, such as heroin or opium, or prescription medications, such as morphine, oxycodone or codeine. Titan is developing Probuphine® a novel, proprietary, potential long-term treatment for opioid dependence. Probuphine is currently in Phase III clinical trials; additional U.S. and E.U. studies are being planned.

Probuphine also is being developed for the potential treatment of chronic pain associated with several diseases.

For more information regarding these clinical trials, please click here or visit www.theaddictionstudy.com.